Cellyan Biotechnology Co annual return on equity
2024
2025
2026
Cellyan Biotechnology Co Return on Equity (ROE) Growth & History (HKPD)
Cellyan Biotechnology Co's return on equity was −15.59% for fiscal 2026.
View full Cellyan Biotechnology Co company overviewCellyan Biotechnology Co annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-03-31 | −15.59% | −15.00 pp |
| 2025 | 2025-03-31 | −0.59% | −55.54 pp |
| 2024 | 2024-03-31 | 54.96% | — |
Cellyan Biotechnology Co return on equity trends
Between the periods ended 2024-03-31 and 2026-03-31, Cellyan Biotechnology Co's return on equity decreased from 54.96% to −15.59%, a change of −70.55 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cellyan Biotechnology Co source filings ↗